No profile data available.
Lexicon Pharmaceuticals, Inc. (LXRX) is a healthcare company in the cardiac treatment pharmaceuticals industry, based in The Woodlands, United States, with about 81 full-time employees.
It reported revenue of $49.80 million for fiscal year 2025, up 60.2% from fiscal year 2024, and net income of -$50.34 million. Its market capitalization was $747.53 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2025; market data as of October 9, 2026.
, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes.
Lexicon Pharmaceuticals reported $49.80 million in revenue for fiscal year 2025, up 60.2% from $31.08 million in fiscal year 2024.
$747.53 million as of October 9, 2026.
Listed companies of a similar size in the same industry (cardiac treatment pharmaceuticals) include Cytokinetics, Incorporated (CYTK), Lexeo Therapeutics, Inc. (LXEO), Cardiol Therapeutics Inc. (CRDL), Tenaya Therapeutics, Inc. (TNYA).